Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections. UK-based and AIM listed, we were founded in 2003 as a spin-out from the University of Southampton.
With over three million people hospitalised each year in the US, respiratory viruses pose a significant threat to global public health and continue to be a major cause of hospitalisations. SNG001 is a host-directed, broad-spectrum antiviral that directly targets the site of infection - the lungs. Its mode of action does not depend on a particular virus or variant.
Data from our trials and subsequent analyses supports the potential of SNG001 to provide clinically important benefits in the treatment of severe viral lung infections. Synairgen now has data from its Phase 3 SPRINTER trial in patients hospitalised with COVID-19, subsequent analyses of different high-risk patient groups within the trial, the 60- and 90-day follow-up Long COVID data, as well as the data from the COPD trial conducted before the pandemic. Using the substantial data collected from these trials, the UNIVERSAL trial, and other data sets, Synairgen is progressing its patient identification strategy to help select patients with the highest clinical need, and who would be most likely to respond to treatment with SNG001. These insights will help inform a robust clinical development programme for SNG001.
With input from clinical advisers, a review of data across our clinical development programmes further supports our approach to investigate SNG001 as a broad-spectrum antiviral for a range of respiratory viral infections.